Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands
Previous
Previous
Doelmatige gezondheidszorg: hoe besteden we onze euro’s het beste?
Next
Next